论文信息 - Switching to unboosted atazanavir reduces bilirubin and triglycerides without compromising treatment efficacy in UGT1A1*28 polymorphism carriers. - 字舞流文

Switching to unboosted atazanavir reduces bilirubin and triglycerides without compromising treatment efficacy in UGT1A1*28 polymorphism carriers.

E. Clementi | Ottavia Viganò | G. di Perri | A. Riva | M. Tarkowski | L. Ferraris | F. Adorni | M. Galli | C. Gervasoni | A. Peri | S. Bonora | G. Milani